TY - JOUR
T1 - Applying nanomedicine in maladaptive inflammation and angiogenesis
AU - Alaarg, Amr
AU - Pérez-Medina, Carlos
AU - Metselaar, Josbert M.
AU - Nahrendorf, Matthias
AU - Fayad, Zahi A.
AU - Storm, Gert
AU - Mulder, Willem J. M.
PY - 2017
Y1 - 2017
N2 - Inflammation and angiogenesis drive the development and progression of multiple devastating diseases such as atherosclerosis, cancer, rheumatoid arthritis, and inflammatory bowel disease. Though these diseases have very different phenotypic consequences, they possess several common pathophysiological features in which monocyte recruitment, macrophage polarization, and enhanced vascular permeability play critical roles. Thus, developing rational targeting strategies tailored to the different stages of the journey of monocytes, from bone marrow to local lesions, and their extravasation from the vasculature in diseased tissues will advance nanomedicine. The integration of in vivo imaging uniquely allows studying nanoparticle kinetics, accumulation, clearance, and biological activity, at levels ranging from subcellular to an entire organism, and will shed light on the fate of intravenously administered nanomedicines. We anticipate that convergence of nanomedicines, biomedical engineering, and life sciences will help to advance clinically relevant therapeutics and diagnostic agents for patients with chronic inflammatory diseases. (C) 2017 Elsevier B.V. All rights reserved
AB - Inflammation and angiogenesis drive the development and progression of multiple devastating diseases such as atherosclerosis, cancer, rheumatoid arthritis, and inflammatory bowel disease. Though these diseases have very different phenotypic consequences, they possess several common pathophysiological features in which monocyte recruitment, macrophage polarization, and enhanced vascular permeability play critical roles. Thus, developing rational targeting strategies tailored to the different stages of the journey of monocytes, from bone marrow to local lesions, and their extravasation from the vasculature in diseased tissues will advance nanomedicine. The integration of in vivo imaging uniquely allows studying nanoparticle kinetics, accumulation, clearance, and biological activity, at levels ranging from subcellular to an entire organism, and will shed light on the fate of intravenously administered nanomedicines. We anticipate that convergence of nanomedicines, biomedical engineering, and life sciences will help to advance clinically relevant therapeutics and diagnostic agents for patients with chronic inflammatory diseases. (C) 2017 Elsevier B.V. All rights reserved
U2 - https://doi.org/10.1016/j.addr.2017.05.009
DO - https://doi.org/10.1016/j.addr.2017.05.009
M3 - Review article
C2 - 28506745
SN - 0169-409X
VL - 119
SP - 143
EP - 158
JO - Advanced drug delivery reviews
JF - Advanced drug delivery reviews
ER -